This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/russia/514382-sputnik-vaccine-covid-protection/
The article has changed 4 times. There is an RSS feed of changes available.
| Version 1 | Version 2 |
|---|---|
| Russia's Sputnik V expected to protect from Covid-19 for at least TWO YEARS, vaccine developer says after Lancet publishes trial | Russia's Sputnik V expected to protect from Covid-19 for at least TWO YEARS, vaccine developer says after Lancet publishes trial |
| (7 months later) | |
| Russia’s Sputnik V coronavirus vaccine is expected to have a prolonged immunization effect, providing protection against the deadly disease for at least two years, the formula's developer told journalists, on Tuesday. | Russia’s Sputnik V coronavirus vaccine is expected to have a prolonged immunization effect, providing protection against the deadly disease for at least two years, the formula's developer told journalists, on Tuesday. |
| The estimated duration of the vaccine's effects was revealed by Alexander Gintsburg, the head of the Gamaleya Research Institute of Epidemiology and Microbiology, which developed Russia's pioneering Sputnik V vaccine. | The estimated duration of the vaccine's effects was revealed by Alexander Gintsburg, the head of the Gamaleya Research Institute of Epidemiology and Microbiology, which developed Russia's pioneering Sputnik V vaccine. |
| Gintsburg held a press briefing alongside other officials marking the publication of the preliminary results of the Phase III trial in the prestigious medical journal The Lancet earlier in the day. | Gintsburg held a press briefing alongside other officials marking the publication of the preliminary results of the Phase III trial in the prestigious medical journal The Lancet earlier in the day. |
| Apart from the estimated lengthy protection it gives against Covid-19, the vaccine also boasts a lack of known severe side effects. Except for an occasional rise of body temperature or minor pains around the injection spot, the vaccine did not cause any long-term adverse effects during the trials. | Apart from the estimated lengthy protection it gives against Covid-19, the vaccine also boasts a lack of known severe side effects. Except for an occasional rise of body temperature or minor pains around the injection spot, the vaccine did not cause any long-term adverse effects during the trials. |
| “Clinical trials have fully confirmed the results that were obtained earlier, in the first and second phases,” Gintsburg stated. “These results indicate the complete safety of this vaccine. No serious complications were found among nearly 30,000 subjects, apart from those non-significant side effects, which were noted during first and second phases.” | “Clinical trials have fully confirmed the results that were obtained earlier, in the first and second phases,” Gintsburg stated. “These results indicate the complete safety of this vaccine. No serious complications were found among nearly 30,000 subjects, apart from those non-significant side effects, which were noted during first and second phases.” |
| Publication of the Phase III trial's results has been already hailed by multiple international scientists. For instance, president of Argentina's society of infectologists, Omar Sued, hailed the vaccine's safety and high efficacy. | Publication of the Phase III trial's results has been already hailed by multiple international scientists. For instance, president of Argentina's society of infectologists, Omar Sued, hailed the vaccine's safety and high efficacy. |
| “The paper, published in The Lancet, confirms successful results and provides additional information about the efficacy and the safety of this vaccine in different subgroups,” Sued stated. | “The paper, published in The Lancet, confirms successful results and provides additional information about the efficacy and the safety of this vaccine in different subgroups,” Sued stated. |
| “From the public health's point of view, the efficacy of the vaccine was very high. The safety profile was very good. The dissemination of this information is vital for informing the scaling up and rollout of this vaccine worldwide.” | “From the public health's point of view, the efficacy of the vaccine was very high. The safety profile was very good. The dissemination of this information is vital for informing the scaling up and rollout of this vaccine worldwide.” |
| Think your friends would be interested? Share this story! | Think your friends would be interested? Share this story! |
| Dear readers and commenters, | |
| We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system. | |
| Sorry for the inconvenience, and looking forward to your future comments, | |
| RT Team. |